CP
RYTM icon

CenterBook Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

CenterBook Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Sell
1,975
-7,051
-78% -$638K 0.01% 673
2026
Q1 		$785K Buy
+9,026
New +$878K 0.04% 392

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CenterBook Partners's RYTM Position: Q2 2026 in Review

CenterBook Partners reduced its Rhythm Pharmaceuticals (RYTM) stake by 78% in Q2 2026, selling an estimated $638K and leaving 1,975 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #673.

CenterBook Partners first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. The position peaked at $785K in Q1 2026. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • CenterBook Partners held 1,975 shares of Rhythm Pharmaceuticals worth $219K as of Q2 2026.
  • CenterBook Partners sold 7,051 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $638K.
  • Rhythm Pharmaceuticals made up 0.01% of CenterBook Partners's portfolio in Q2 2026, its #673 holding.
  • CenterBook Partners first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • CenterBook Partners's Rhythm Pharmaceuticals position peaked at $785K in Q1 2026.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.